GSK plc vs Sanofi S.A.: Strategic Comparison

This in-depth comparison examines GSK plc and Sanofi S.A. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching GSK plc on its own, evaluating Sanofi S.A., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between GSK plc and Sanofi S.A. is widest.

On the headline numbers, GSK plc reports annual revenue of ~$43.1B against ~$49.3B for Sanofi S.A., while their respective market capitalizations stand at $100.0B and $100.0B. GSK plc is headquartered in United Kingdom and Sanofi S.A. operates from France, and those different home markets shape how each company competes.

GSK plc: GSK plc is listed in London (LSE: GSK) and New York (NYSE: GSK) and is a FTSE 100 constituent. It operates in about 70 countries with 33 manufacturing sites and about 66,800 employees. The company focuses on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Well-known products include Shingrix, Arexvy, Trelegy Ellipta, Ventolin, Nucala, Dovato and Cabenuva.

Sanofi S.A.: Sanofi S.A. is headquartered in Paris and listed on Euronext Paris (SAN) and Nasdaq (SNY ADRs). It employed 74,846 people at the end of 2025. The company sells Dupixent with Regeneron, the infant RSV antibody Beyfortus with AstraZeneca, a large influenza and pediatric vaccine portfolio, rare disease enzyme therapies from Genzyme, and older medicines such as Lantus, Toujeo, Plavix and Lovenox.

GSK plc and Sanofi S.A. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between GSK plc and Sanofi S.A..

GSK plc business model: GSK makes money by discovering, manufacturing and selling prescription medicines and vaccines, mostly to health systems, insurers, pharmacies and governments. Its sales are reported in three groups. Specialty Medicines (~$17.8 billion (£13.5 billion) in 2025, about 41% of sales) covers HIV through ViiV Healthcare, respiratory and immunology biologics such as Nucala and Exdensur, and oncology drugs such as Jemperli, Ojjaara and Blenrep. Vaccines (~$12.1 billion (£9.2 billion), about 28%) are led by Shingrix for shingles, the Bexsero and Menveo meningitis vaccines and the Arexvy RSV vaccine. General Medicines (~$13.2 billion (£10.0 billion), about 31%) includes established inhalers such as Trelegy and Ventolin and antibiotics like Augmentin. GSK also earns royalty income on licensed products.

Sanofi S.A. business model: Sanofi makes money by developing, manufacturing and selling prescription medicines and vaccines to hospitals, pharmacies, wholesalers, insurers and government health systems. In 2025 its ~$49.3 billion (EUR43.6 billion) of net sales broke down into Dupixent (~$17.7 billion (EUR15.7 billion)), pharma launches such as ALTUVIIIO and Ayvakit (~$4.41 billion (EUR3.9 billion)), vaccines (~$8.93 billion (EUR7.9 billion)) and other established medicines (~$18.2 billion (EUR16.1 billion)). The United States generated ~$25.1 billion (EUR22.2 billion) and Europe ~$10.4 billion (EUR9.2 billion). Dupixent profits are shared with Regeneron under their long-running antibody collaboration.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of GSK plc stack up against those of Sanofi S.A..

GSK plc competitive advantage: GSK's advantages are scale in vaccine manufacturing, a long-acting HIV portfolio through ViiV Healthcare, and the AS01 adjuvant system used in Shingrix and Arexvy. Vaccines are hard to copy because they depend on biological manufacturing, cold-chain distribution and long-term government contracts. ViiV's long-acting injectables, Cabenuva for treatment and Apretude for prevention, aim to move patients onto newer regimens ahead of the dolutegravir patent expiry.

Sanofi S.A. competitive advantage: Sanofi's edge rests on two assets that are hard to copy. Dupixent is approved across a long list of type 2 inflammatory diseases, from atopic dermatitis and asthma to COPD and chronic spontaneous urticaria, which gives it unusual breadth for a single antibody. Its vaccines business, built on the former Sanofi Pasteur, runs large-scale influenza and pediatric vaccine manufacturing that few rivals can match, and it adds rare disease know-how inherited from Genzyme.

Future prospects matter as much as current results. The growth strategies below explain how GSK plc and Sanofi S.A. each plan to expand from here.

GSK plc growth strategy: Under Luke Miels, GSK is combining targeted acquisitions with faster R&D. Deals since 2025 include IDRx (GIST, January 2025), efimosfermin from Boston Pharmaceuticals ($1.2 billion upfront, July 2025) and Nuvalent ($10.6 billion, completed July 2026). In July 2026 GSK identified 7 assets across 18 indications in oncology, respiratory, hepatology and vaccines to speed up, raised its 2026 phase III start target from 10 to more than 20, and launched a cost programme to fund that investment.

Sanofi S.A. growth strategy: Sanofi's strategy, set under Paul Hudson's 2019 'Play to Win' plan and now being tightened by Belén Garijo, is to concentrate on immunology, rare diseases, neurology and vaccines. Key steps were exiting most diabetes and cardiovascular research, separating consumer health (Opella, majority sold to CD&R in April 2025) and buying specialty assets such as Provention Bio (2023), Inhibrx's AATD drug (2024) and Blueprint Medicines (2025). Garijo has stressed execution discipline and capital allocation, and in Q2 2026 she discontinued several late-stage programs.

A closer look at the financial trajectory of GSK plc and Sanofi S.A. rounds out the comparison.

GSK plc: GSK reported 2025 turnover of ~$43.2 billion (£32.7 billion) (+4% at actual rates, +7% at constant currency), operating profit of ~$10.4 billion (£7.9 billion), profit attributable to shareholders of ~$7.52 billion (£5.7 billion), and earnings per share of 141.1p. Cash generated from operations was ~$11.7 billion (£8.9 billion) and free cash flow ~$5.28 billion (£4.0 billion). In Q2 2026, sales rose 5% to ~$11.1 billion (£8.4 billion) and core operating profit rose 7% to ~$3.7 billion (£2.8 billion), beating consensus, while reported operating profit fell to ~$635 million (£481 million) because of the camlipixant impairment. H1 2026 turnover was ~$21.1 billion (£16.0 billion). GSK reaffirmed 2026 guidance of 3% to 5% turnover growth and 7% to 9% core operating profit growth, expects a 70p dividend for 2026, and launched a three-year plan targeting ~$2.51 billion (£1.9 billion) of annual savings by 2029.

Sanofi S.A.: Sanofi's finances now hinge on Dupixent. Sales of the antibody reached ~$17.7 billion (EUR15.7 billion) in 2025 and ~$5.88 billion (EUR5.2 billion) in Q2 2026 alone, up 37.6%, and management has targeted around $24.9 billion (EUR22 billion) by 2030. Group net sales grew from ~$46.4 billion (EUR41.081 billion) in 2024 to ~$49.3 billion (EUR43.626 billion) in 2025, free cash flow was about $9.15 billion (EUR8.1 billion), and Q2 2026 business EPS rose 33.3% at CER to EUR2.09. The 2025 Opella deal turned the consumer business into a 48.2% equity stake and brought in cash that Sanofi used for acquisitions such as Blueprint Medicines and share buybacks.